Managing the pandemic has been a massive, once-in-a-lifetime challenge. Life sciences enterprises throughout the world have responded with leadership and are emerging stronger. To deal with the worldwide problem, traditional competitors teamed up to speed up research and develop the world's fastest new vaccine. Digitization is extending the scope of new possibilities in the life sciences industry with the introduction of this `new-normal.' Redefined employment conditions, a shift in health-care delivery, and novel collaborations to produce efficiencies are just a few instances of how technological developments are enabling this unprecedented transition. While pharmaceutical innovation is saving the globe, biopharma and medtech businesses now have a chance to keep up the trend. We are getting closer to true precision medicine and a future of health in which we can learn from every radically interoperable data item in the context of every patient. When we look back in 20 years, 2020 may very well be remembered as the year when life sciences companies finally broke free from their 20th-century models and entered a new age. The Life Sciences industry is at a crossroads. Biopharma and medtech companies will be looking for new ways to produce value and new metrics to make sense of today's wealth of data in order to plan for the future and stay relevant in the ever-changing business landscape. The use of IoT, machine learning, additive manufacturing, and augmented reality by medtech firms has the potential to increase efficiency and solve problems. A new generation of AI startups is redefining how novel pharmaceuticals are developed. Traditional thinking and legacy cultures should not put biopharma companies at a disadvantage when it comes to AI talent. Emerging technologies may also help to drive change at every stage of the supply chain, resulting in better value for patients.The life science industry's new growth frontiersEditor's NoteEditor's NotePHARMA & LIFE SCIENCESEDITION
< Page 2 | Page 4 >